All Oncology News

The European Medicines Agency has validated a marketing authorization application for elacestrant for estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

John Mascarenhas, MD, discussed the effect of the data from MANIFEST on the treatment landscape and the future of adding active agents to ruxolitinib for treatment of myelofibrosis.

Non-Hispanic Black, Hispanic, and Asian patients with cancer are significantly more likely to experience delays in receiving intensity-modulated radiotherapy.

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

The European Commission has approved the bevacizumab biosimilar, CT-P16, for the treatment of patients with metastatic breast cancer, non–small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer, and cervical cancer.

Maintenance therapy with rucaparib following platinum-based chemotherapy prolonged progression-free survival compared with placebo in patients with DNA repair–deficient-positive, metastatic urothelial cancer.

Benjamin Levy, MD, discusses treatment considerations for the integration of trastuzumab deruxtecan into practice and what this approval signals for the future of the field.

The addition of galunisertib to neoadjuvant chemoradiotherapy improved complete response rates in patients with locally advanced rectal cancer, according to findings from a phase 2 study.

The FDA has granted an orphan drug designation to the fixed-dose combination capsule of the PARP inhibitor senaparib and temozolomide for the treatment of adult patients with small cell lung cancer.

Jashodeep Datta, MD, associate member of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, led a study recently published in the journal Oncogene that helps to explain pancreatic cancer’s notorious virulence and resistance to therapy.

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

Matthew J. Frigault, MD, discusses the findings from a phase 1 trial investigating the safety and efficacy of CART-ddBCMA in patients with multiple myeloma in whom all previous lines of treatment had failed and shares additional research opportunities for the CAR T-cell therapy.

The United Kingdom Medicines and Healthcare Products Regulatory Agency has extended the conditional marketing authorization of fam-trastuzumab deruxtecan-nxki for single-agent use in adult patients in Great Britain who have HER2-positive unresectable or metastatic breast cancer and have received 1 or more prior HER2-based regimens.

The European Commission has approved melphalan flufenamide for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies.

Elotuzumab plus pomalidomide and dexamethasone demonstrated a significant improvement in overall survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma who previously received treatment with lenalidomide and a proteasome inhibitor.

Julian Schink, MD, discusses a study evaluating racial differences in the mutational landscape of serous endometrial cancer, underscores the need for appropriate genomic testing and treatment for Black women with the disease, and explains the importance of racial representation across clinical trials.

The FDA has lifted a partial clinical hold on the open-label, dose-escalating phase 1/2 TakeAim Lymphoma trial investigating the safety and efficacy of emavusertib in patients with relapsed or refractory B-cell malignancies.

Dana-Farber Brigham Cancer Center opened a new facility in Foxborough, MA, which provides world-class cancer care to patients in southern Massachusetts and Rhode Island.

Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.

The combination of lenalidomide and rituximab demonstrated durable safety and efficacy that was comparable to that achieved with rituximab plus chemotherapy in previously untreated patients with follicular lymphoma, according to 6-year data from the phase 3 RELEVANCE trial.

Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.

The FDA has approved betibeglogene autotemcel (Zynteglo) for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Katherine Tkaczuk, MD, discusses practice-changing data across breast cancer subtypes that were discussed at the 2022 ASCO Annual Meeting, including data from DESTINY-Breast04 and the phase 3 PALOMA-2 trial, plus the utilization of CDK4/6 inhibitors and PARP inhibitors for select patients with breast cancer.

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

Treatment with avapritinib led to clinically meaningful and statistically significant improvements in patient-reported symptoms and objective measures of mast cell burden in patients with non-advanced systemic mastocytosis.

The FDA has accepted a new drug application for momelotinib for the treatment of patients with myelofibrosis.

CDK4/6 inhibitors have carved out a substantial role in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer.

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

The Guardant Reveal assay has been expanded for the detection of minimal residual disease and disease recurrence in patients with early-stage breast cancer and lung cancer.